4.5 Article

Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 69, Issue 9, Pages 1840-1849

Publisher

WILEY
DOI: 10.1002/art.40166

Keywords

-

Categories

Funding

  1. Mary Catherine Piazza Lupus Research Fund
  2. NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS]) [R03-AR-066337]
  3. Arthritis National Research Foundation
  4. NIH (NIAMS) [K08-AR-063668]
  5. Idera Pharmaceuticals

Ask authors/readers for more resources

Objective. The inflammasome complex is a driver of organ damage in patients with systemic lupus erythematosus (SLE). Although type I interferons (IFNs) are well established as mediators of SLE pathogenesis, their role in inflammasome activation in SLE has not been assessed. The aim of this study was to examine type I IFNs as regulators of the inflammasome. Methods. SLE patients fulfilled >= 4 American College of Rheumatology criteria and were recruited from the University of Michigan Lupus Cohort. Primary monocytes were isolated from SLE patients or healthy controls by negative selection, treated with inflammasome activators in the presence or absence of IFN alpha, and IL-1 beta secretion was measured by enzyme-linked immunosorbent assay. Expression levels of IFN and inflammasome-related molecules were assessed by real-time polymerase chain reaction and Western blotting. IFN regulatory factor 1 (IRF-1) expression was specifically down-regulated by small interfering RNA (siRNA) transfection and a chemical inhibitor. Results. Monocytes from patients with SLE exhibited increased expression and enhanced activation of the inflammasome by ATP when compared with control monocytes. Expression of inflammasome and IFN-regulated genes was significantly correlated in monocytes from SLE patients but not in control monocytes. Inflammasome activity was increased after prolonged exposure to IFN alpha. Reduction of IRF-1 expression via siRNA blocked caspase 1 up-regulation after treatment with IFN alpha. Importantly, hyperactivity of the inflammasome in the monocytes of SLE patients was significantly reduced after knockdown or inhibition of IRF-1. Conclusion. Prolonged type I IFN exposure, as seen in SLE patients, primes monocytes for robust inflammasome activation in an IRF-1-dependent manner. IRF-1 inhibition may serve as a novel target for treatment of SLE-associated inflammation and organ damage.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available